ERBB2 and cancer: Interrogating a large meta-analysis of published breast cancer microarray datasets [11] in which cancers could be segregated according to PAM50-derived intrinsic subtypes [12], revealed that increased expression of TMEPAI in HER2-expressing breast cancers was associated with significantly poorer patient prognosis (Fig. 2).